Syklomics Biotechnology · Hemoglobinopathy · Drug Discovery

Drug discovery,
finally
intentional.

A multi-omics platform accelerating therapy development for sickle cell disease — built by someone who lives with it.

Explore the PlatformOur Science
100M+
People with hemoglobinopathies
50M+
Affected by sickle cell globally
3–5×
Faster to market via repurposing
60%
Cost reduction via repurposing
The Problem

Drug discovery is
slow, expensive,
and not intentional.


The current gold standard for sickle cell disease — Hydroxyurea — was an accidental discovery originally developed for cancer. It took decades to reach SCD patients. We asked: what if this process were deliberate?

20yr
Average timeline from drug discovery to patient access — a timeline SCD patients simply cannot afford.
$2.6B
Average cost to bring a novel drug to market. Repurposing can cut this by up to 60%.
<25%
Of affected patients are adequately served by current treatments due to differential drug response.
#1
Nigeria carries the highest global burden of SCD — and is at the centre of our data strategy.
The Platform

Three layers.
One map.

Syklomics integrates genomics, proteomics, and metabolomics into a unified biological map of hemoglobinopathy — then surfaces repurposing candidates with precision no single data source can match.

01
Drug Repurposing
Our core approach. We identify FDA-approved drugs whose mechanism of action overlaps with biological targets from our multi-omics data — compressing years of discovery into months.
02
Novel Drug Design
Where no suitable compound exists, generative models design new compounds for identified biological targets — extending the platform beyond the existing pharmacopoeia.
03
Biomarker Discovery
Our longitudinal patient dataset surfaces predictors of drug response and complication risk — creating licensing value for pharma partners and companion diagnostic developers.
The Science

Beyond the mutation.
The full biological network.

01
Genomics
Identifies not just the primary mutation but genetic modifiers and variants that influence disease severity — the foundation of every patient profile.
Mutation · Variants · Modifiers
02
Proteomics
Reveals how the mutation alters protein expression and interaction networks — exposing dysfunctional pathways that genomics alone cannot identify.
Protein networks · Pathways
03
Metabolomics
Captures the metabolic signature of the disease — oxidative stress markers, inflammatory mediators, and red blood cell energy metabolism between patients of different severity.
Metabolism · Inflammation

“Hydroxyurea took decades to reach SCD patients. It was an accidental discovery. Our platform exists to make that process deliberate, data-driven, and fast.”

Fatima Oyawoye, CEO & Co-founder
Our Edge

What our competitors
don't have.

01
Proprietary Longitudinal Dataset
A fully integrated, multi-omics database built specifically for hemoglobinopathy — capturing clinical severity, longitudinal history, treatment response, and full omics profiles on the same patients. This dataset does not exist anywhere in the world today.
Existing platforms rely on public databases like GEO and UniProt — not disease-focused, lacking clinical depth.
02
Multi-Omics, Not Just Genomics
Genomics shows where a mutation is. It doesn't show how it translates into disease. Our proteomics and metabolomics add two additional biological layers — revealing targets invisible to single-omic approaches.
Most AI drug discovery companies are genomics-only. We go three layers deep.
03
Repurposing First
Novel drug design means a decade to market minimum. Our repurposing-first strategy leverages existing safety profiles, abbreviated Phase I trials, and accelerated FDA pathways — putting validated candidates in patients' hands years faster.
Most platforms are racing on novel compounds. We're already on a shorter track.
04
Disease-First Founder Perspective
Our CEO has sickle cell disease and has spent a decade researching it. Our CTO brings the bioinformatics depth. The combination of lived experience, clinical research, and technical execution is extraordinarily rare in biotech.
The best drug for SCD shouldn't come from someone who has never met a patient with it.
The Founders

Built by people
who live the mission.

FO
Fatima Oyawoye
CEO · Co-founder
PhD researcher with nearly a decade of experience in omics landscapes and hemoglobinopathy drug discovery. Fatima has sickle cell disease — giving her a perspective as patient, researcher, and community advocate that shapes every decision Syklomics makes.
“I know what it means to wait for a drug that doesn't serve you. That's not an abstract problem for me.”
PI
Pamilerin Idowu
CTO · Co-founder
Technical architect at Syklomics with over a decade of experience as a full-stack software engineer and a strong data engineering background. Pamilerin leads engineering across the entire platform — building the multi-omics data pipeline, the disease knowledge graph, and the AI models that surface drug candidates, alongside the application layer that makes it usable.
“The science is ready. The data infrastructure is buildable. What's missing is intentionality. That's what we're building.”
Get Involved

The next SCD breakthrough
won't happen by accident.

Whether you're a pharma partner, an investor, a clinician, or a patient — we want to hear from you. This platform is for the 100 million people living with hemoglobinopathies.

Contact UsLearn More